Other languages Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
27.47 ^USD	-7.26%		-4.35%	+203.54%

May. 17	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing	MT
May. 15	Transcript : Avidity Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing	May. 17
Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors	May. 15
Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1	May. 08
Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1	May. 08
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	Apr. 04
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	Apr. 04
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	Mar. 15
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	Mar. 13
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	Mar. 05
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	Mar. 04
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	Feb. 29
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Avidity Biosciences Receives US FDA's Rare Pediatric Disease Designation for AOC 1044 in Duchenne Muscular Dystrophy	Feb. 20
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping	Feb. 20
Avidity Biosciences Appoints Strategy Chief, Plans to Start Phase 3 Myotonic Dystrophy Type 1 Study	Jan. 05
Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024	Jan. 05
Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board	Jan. 05
Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44? Trial for Duchenne Muscular Dystrophy	Dec. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Other languages

Filters